The OrbusNeich Combo Dual Therapy stent was featured at the Joint Interventional Meeting (JIM) 2014 in Rome, February 13-15.
According to a press release issued by the company, Robbert de Winter, of the Academic Medical Centre, Amsterdam, The Netherlands, presented an update on the REMEDEE Registry, a post-market registry to evaluate the long-term safety and performance of the Combo Dual Therapy stent in routine clinical practice, confirming that the registry is three quarters toward its goal of enrolling 1,000 patients.
“The Combo technology has been one of the most innovative advancements in the interventional cardiology field for some time,” said de Winter. “I appreciate OrbusNeich’s commitment to continued research and development and the advancement of stent technology for the benefit of our patients. This is an exciting technology, and I look forward to the results of the REMEDEE registry.”
The Combo stent was also featured in two live case demonstrations, the press release reports.
The first live case was performed at Bonn University Hospital in Bonn, Germany. The patient, an 82 year old female with a history of myocardial infarction, had a lesion in the left anterior descending (LAD) artery. The Combo stent placed was 2.5mm in diameter by 13mm in length and resulted in a complete restoration of thrombolysis in myocardial infarction flow.
The second live case was performed at the Columbus Hospital in Milano, Italy. The patient had a calcified lesion of the left anterior descending artery, and four Combo stents were placed in the proximal (3.5mm x 9mm), medium (3.5mm x 18mm), medium distal (3.5mm x 33mm) and distal (2.5mm x 23mm) segments. In addition, OrbusNeich’s Sapphire non-compliant balloons were used.
